Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $38.41 Consensus Price Target from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $38.4118.

A number of equities research analysts have weighed in on DYN shares. Sanford C. Bernstein set a $23.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $40.00 in a report on Wednesday, December 10th. Royal Bank Of Canada raised their price target on Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, HC Wainwright upped their price target on shares of Dyne Therapeutics from $46.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 8th.

Institutional Trading of Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Dyne Therapeutics by 14.9% during the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after purchasing an additional 1,455,151 shares in the last quarter. TCG Crossover Management LLC lifted its stake in Dyne Therapeutics by 22.5% during the 3rd quarter. TCG Crossover Management LLC now owns 4,615,144 shares of the company’s stock valued at $58,382,000 after acquiring an additional 848,484 shares during the period. JPMorgan Chase & Co. lifted its stake in Dyne Therapeutics by 9.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after acquiring an additional 278,466 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Dyne Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 3,263,429 shares of the company’s stock valued at $63,844,000 after acquiring an additional 395,824 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Dyne Therapeutics during the second quarter valued at approximately $30,378,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Up 1.1%

DYN stock opened at $16.99 on Tuesday. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $25.00. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -4.64 and a beta of 1.30. The business’s 50 day moving average price is $18.69 and its two-hundred day moving average price is $16.50. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.